.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX02_Sorafenib.Sorafenib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX02_Sorafenib.Sorafenib| name: | Sorafenib |
| ATC code: | L01EX02 | route: | oral |
| n-compartments | 2 |
Sorafenib is a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and differentiated thyroid carcinoma. It acts by inhibiting tumor cell proliferation and angiogenesis.
Pharmacokinetic parameters reported in adult cancer patients (solid tumors), both male and female, after multiple oral doses.
Jain, L, et al., & Figg, WD (2011). Population pharmacokinetic analysis of sorafenib in patients with solid tumours. British journal of clinical pharmacology 72(2) 294–305. DOI:10.1111/j.1365-2125.2011.03963.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21392074
Chen, Y, et al., & Pithavala, YK (2015). Axitinib plasma pharmacokinetics and ethnic differences. Investigational new drugs 33(2) 521–532. DOI:10.1007/s10637-015-0214-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/25663295
Huh, KY, et al., & Chung, JY (2021). Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib. Pharmaceutics 13(5) –. DOI:10.3390/pharmaceutics13050629 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33925058